Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT07828548

Effect of the Ansileve Supplement on the Well-being of Parents of Children Who Have Experienced a Medical Emergency: A Randomized Controlled Study

Conditions: Parenting Anxiety, Child Hospitalization, Psychological Well-being

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Phase: NA
Enrollment: 96
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Summary

The goal of this randomized, double-blind, placebo-controlled clinical trial is to evaluate whether the dietary supplement Ansileve (Ansileve SOS spray and Ansileve capsules) can improve psychological well-being and parental functioning in mothers and fathers of children experiencing an acute medical event requiring hospital care. The main questions are: 1. Does acute administration of Ansileve SOS spray improve maternal functioning in the short term, as measured by the Barkin Index of Maternal Functioning (BIMF), compared with placebo? 2. Does Ansileve SOS spray and the subsequent 30-day supplementation with Ansileve capsules reduce anxiety symptoms and improve emotional well-being in parents, compared with placebo? Researchers will compare participants receiving Ansileve SOS spray and/or Ansileve capsules with participants receiving matching placebo products to determine whether the intervention improves parental functioning, reduces anxiety symptoms, and supports psychological recovery after a stressful event involving their child. Participants will: * Be mothers and fathers (≥18 years) of children admitted for an acute medical event at the Pediatria Immunoreumatologia Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico * Complete validated questionnaires assessing functioning (BIMF, only mothers), emotional impact of the event \[Impact of Event Scale - Revised (IES-R)\], and anxiety symptoms \[Generalized Anxiety Disorder Scale (GAD-7)\] at baseline and during follow-up * Receive either Ansileve SOS spray or placebo spray at study enrolment. * Take either Ansileve capsules or placebo capsules daily for 30 days according to the assigned treatment group * Complete a follow-up assessment to evaluate treatment adherence and possible adverse events.

Eligibility Criteria

Inclusion Criteria: * Mothers and fathers of children presenting to the Pediatria Immunoreumatologia Unit of the De Marchi Pediatric Clinic for an acute medical event * Age ≥18 years * Provision of written informed consent Exclusion Criteria: * Known psychiatric disorders * Failure to provide written informed consent * Insufficient proficiency in the Italian language * Pregnancy or breastfeeding * Known allergy or intolerance to one or more components of the food supplement

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07828548). StuddyBuddy aggregates publicly available trial information.